

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>TM</sup>

## EDITORIAL

### Good Antimicrobial Stewardship in the Hospital: Fitting, but Flagrantly Flagging

DALE N. GERDING, MD

253

## ORIGINAL ARTICLES

### Practices to Improve Antimicrobial Use at 47 US Hospitals: The Status of the 1997 SHEA/IDSA Position Paper Recommendations

RACHEL M. LAWTON, MPH; SCOTT K. FRIDKIN, MD; ROBERT P. GAYNES, MD; JOHN E. MCGOWAN, JR, MD;  
AND THE INTENSIVE CARE ANTIMICROBIAL RESISTANCE EPIDEMIOLOGY (ICARE) HOSPITALS

256

### Nosocomial Infections in Pediatric Patients: A European, Multicenter Prospective Study

JOSETTE RAYMOND, MD; YANNICK AUJARD, MD; THE EUROPEAN STUDY GROUP

260

### Comparison of Higher-Dose Intradermal Hepatitis B Vaccination to Standard Intramuscular Vaccination of Healthcare Workers

ELIZABETH A. HENDERSON, PhD; THOMAS J. LOUIE, MD, FRCPC; KARAM RAMOTAR, PhD;  
DONNA LEDGERWOOD, RN, BN; KAREN MYRTHU HOPE, MSC; AGNES KENNEDY, RN, BN

264

## CONCISE COMMUNICATIONS

### Evidence of Delays in Transferring Patients With Methicillin-Resistant *Staphylococcus aureus* or Vancomycin-Resistant *Enterococcus* to Long-Term-Care Facilities

ELIZABETH A. BRYCE, MD, FRCPC; SHELLEY M. TIFFIN, ART, BMLSC; JUDITH L. ISAAC-RENTON, MD, FRCPC;  
CHARLES J. WRIGHT, MD, FRCPC

270

### The Incidence and Risk Factors of Ventilator-Associated Pneumonia in a Riyadh Hospital

ZIAD A. MEMISH, MD, CIC; GWEN CUNNINGHAM, RN, CIC; GBOLAHAN A. ONI, PhD; W. DJAZMATI, MD

271

## ISSUES IN SURGERY

### O<sub>2</sub> in Y2K: Not An Airtight Case

JAMES T. LEE, MD, PhD

274

## STATISTICS FOR HOSPITAL EPIDEMIOLOGY

### Diagnostic Tests: Distinguishing Good Tests From Bad and Even Ugly Ones

BARRY M. FARR, MD, MSC; DAVID E. SHAPIRO, PhD

278

Continued inside.

# Are You Doing All You Can to Stop Methicillin-Resistant *Staphylococcus aureus* Outbreaks Where They Originate...

The Nares

- *Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.<sup>1</sup>
- In a hospital study, *Bactroban* Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.<sup>2</sup>
- Excellent safety profile<sup>1</sup>

The most frequently reported adverse events were headache (9%), rhinitis (6%), respiratory disorder (including upper respiratory tract congestion) (5%), pharyngitis (4%) and taste perversion (3%). Safety in children under 12 years of age has not been established in controlled clinical trials.

Contraindications ... Do not use *Bactroban* Nasal in patients with known hypersensitivity to any of the constituents of the product.

Please see brief summary of prescribing information on adjacent page.

**References:** 1. *Bactroban*® Nasal prescribing information, 1995. 2. Reagan DR, Dula RT, Palmer BH, et al. Control of MRSA in a VAMC with limited resources. Prog Abstr 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., Sept. 29-Oct. 2, 1991, p 104.

**SB** **SmithKline Beecham**  
Pharmaceuticals

Published online by Cambridge University Press

BN2760 ©SmithKline Beecham, 1999 Philadelphia, PA

Single-use tube  
(actual size)



**Bactroban**  
**Nasal** mupirocin  
calcium  
2% ointment for intranasal use

**BACTROBAN® NASAL** (mupirocin calcium ointment), 2%  
**Brief summary. For complete prescribing information, see package insert.**

**INDICATIONS AND USAGE**

*Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *Staphylococcus aureus* in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

**NOTE:**

- (1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus*.
- (2) There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infection in any patient population.
- (3) Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.

**CONTRAINDICATIONS**

*Bactroban* Nasal is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

**WARNINGS**

**AVOID CONTACT WITH THE EYES.** Application of *Bactroban* Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from *Bactroban* Nasal, usage should be discontinued.

**PRECAUTIONS**

**General:** As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See **DOSE AND ADMINISTRATION** in complete prescribing information.)

**Information for Patients:** Patients should: apply approximately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nostril; avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gently massage after application to spread the ointment throughout the inside of the nostrils; and discontinue using *Bactroban* Nasal and call a health care practitioner if sensitization or severe local irritation occurs.

**Drug Interactions:** The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to 40 times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m<sup>2</sup> basis and revealed no evidence of impaired fertility from mupirocin sodium.

**Pregnancy: Teratogenic Effects. Pregnancy Category B.** Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m<sup>2</sup> basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

**Pediatric Use:** Safety in children under the age of 12 years has not been established. (See **CLINICAL PHARMACOLOGY** in complete prescribing information.)

**ADVERSE REACTIONS**

**Clinical Trials:** In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received *Bactroban* Nasal ointment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (38/210) of adults treated with *Bactroban* Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respiratory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; and pruritus, 1%.

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

**OVERDOSAGE**

Following single or repeated intranasal applications of *Bactroban* Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.

Manufactured by **DPT Laboratories**, San Antonio, TX 78215  
 Distributed by **SmithKline Beecham Pharmaceuticals**, Philadelphia, PA 19101

BRS-BN:L3


**HATS OFF TO FIRST CLASS SERVICE**


At SLACK Incorporated we believe our subscribers are first class people. That's why we do everything possible to publish first class journals. And, that's why we maintain a **TOLL-FREE CUSTOMER SERVICE HOTLINE**. For the first class customer service you deserve, call:


**1-800-257-8290**


**Talk to a SLACK Customer Service Representative about:**

 **Subscriptions.** Subscribing by phone is quick and easy; it only takes a minute and Visa and MasterCard are accepted.

 **Change of Address.** Please notify us four weeks in advance to assure prompt delivery to your new address.

 **Renewals.** Early subscription renewal helps avoid possible interruptions in service.

 **Questions or Problems.** Delivery problems or questions about your subscriptions can be handled instantly.



**SLACK** 6900 Grove Road,  
 Thorofare, NJ 08086

Consumer Information Catalog  
 www.pueblo.gsa.gov

9 out of 10 mice prefer the Consumer Information Catalog online. Just point and click your way to [www.pueblo.gsa.gov](http://www.pueblo.gsa.gov) and you'll find more than 250 free publications ready to read or download.

U.S. General Services Administration

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

## EDITORIAL ADVISORY BOARD

### EDITORIAL OFFICES

Vanderbilt University School of Medicine  
A-1131 Medical Center North  
Nashville, TN 37232-2637  
(615) 343-1095; (615) 343-1882 (FAX)  
Email: iche@mcmail.vanderbilt.edu

### EDITOR

Michael D. Decker, MD, MPH

### MANAGING EDITOR

Susan Cantrell

### STATISTICAL EDITOR

Beverly G. Mellen, PhD

### SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

### ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

### SECTION EDITORS

#### Beyond Infection Control:

#### The New Hospital Epidemiology

Bryan P. Simmons, MD

Stephen B. Kritchewsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

#### Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

#### Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

#### From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

#### Information Management

John A. Sellick, DO

Buffalo, New York

#### The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

#### Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

#### Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

#### Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

#### SHEA News

Andreas Voss, MD, PhD

Nijmegen, The Netherlands

#### Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

#### Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

#### Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

- Jacques F. Acar, MD Paris, France  
J. Wesley Alexander, MD Cincinnati, Ohio  
Paul Arnow, MD Chicago, Illinois  
Graham A.J. Ayliffe, MD Birmingham, United Kingdom  
Neil L. Barg, MD Yakima, Washington  
Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia  
John M. Boyce, MD Providence, Rhode Island  
Professor Dr. Ilja Braveny Munich, Germany  
Christian Brun-Buisson, MD Creteil, France  
Charles Bryan, MD Columbia, South Carolina  
Donald E. Craven, MD Boston, Massachusetts  
Sue Crow, MSN, RN, CIC Shreveport, Louisiana  
Franz Daschner, MD Freiburg, Germany  
Leigh G. Donowitz, MD Charlottesville, Virginia  
Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin  
Theodore C. Eickhoff, MD Denver, Colorado  
Bruce Farber, MD Manhasset, New York  
Victoria J. Fraser, MD St. Louis, Missouri  
Peter C. Fuchs, MD, PhD Black Butte, Oregon  
Richard A. Garibaldi, MD Farmington, Connecticut  
Robert Gaynes, MD Atlanta, Georgia  
Velvi Greene, PhD, MPH Beer Sheva, Israel  
David W. Gregory, MD Nashville, Tennessee  
David K. Henderson, MD Bethesda, Maryland  
Peter N.R. Heseltine, MD Los Angeles, California  
Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina  
Marguerite McMillan Jackson, RN, PhD San Diego, California  
Janine Jagger, MPH, PhD Charlottesville, Virginia  
William R. Jarvis, MD Atlanta, Georgia  
Douglas S. Kernodle, MD Nashville, Tennessee  
Robert H. Latham, MD Nashville, Tennessee  
Lewis B. Lefkowitz, MD Nashville, Tennessee  
Hsieh-Shong Leu, MD, MSc Taipei, Taiwan  
Jack Levy, MD Brussels, Belgium  
Victor Lorian, MD Bronx, New York  
Dennis G. Maki, MD Madison, Wisconsin  
William J. Martone, MD Bethesda, Maryland  
Allison McGeer, MD Toronto, Ontario, Canada  
John E. McGowan, Jr., MD Atlanta, Georgia  
Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada  
Robert R. Muder, MD Pittsburgh, Pennsylvania  
Joseph M. Mylotte, MD, CIC Buffalo, New York  
Lindsay Nicolle, MD Winnipeg, Manitoba, Canada  
Juhani Ojajarvi, MD Helsinki, Finland  
Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota  
Jan Evans Patterson, MD San Antonio, Texas  
Sindy M. Paul, MD Trenton, New Jersey  
Michael A. Pfaller, MD Iowa City, Iowa  
Samuel Ponce de Leon, MD, MSc Mexico City, Mexico  
Isaam Raad, MD Houston, Texas  
Manfred L. Rotter, MD, DipBact Vienna, Austria  
Theodore Sacks, MD Jerusalem, Israel  
William E. Scheckler, MD Madison, Wisconsin  
Kent Sepkowitz, MD New York City, New York  
Denis Spelman, MD Prahran Victoria, Australia  
Michael L. Tapper, MD New York, New York  
Clyde Thornsberrry, PhD Brentwood, Tennessee  
Professor Leonid P. Titov Minsk, Republic of Belarus  
Timothy R. Townsend, MD Millwood, Virginia  
Antoni Trilla, MD, PhD Barcelona, Spain  
Professor Wang Shu-Qun Beijing, People's Republic of China  
J. John Weems, Jr., MD Greenville, South Carolina  
Robert A. Weinstein, MD Chicago, Illinois  
Professor Dr. W. Weuffen Greifswald, Germany  
Sergio B. Wey, MD São Paulo, Brazil  
Rebecca Wurtz, MD Evanston, Illinois

### SLACK Incorporated

6900 Grove Road  
Thorofare, New Jersey 08086  
(856) 848-1000

#### Vice President/Group Publisher

Richard N. Roash

#### Publisher

John C. Carter

#### Editorial Director

Jennifer Kilpatrick

#### Production Editor

Shirley P. Strunk, ELS

#### Assistant Editor

Eileen C. Anderer

#### Editorial Assistant

Aileen Schneider

#### Circulation Manager

Lester J. Robeson, CCCP

#### Production Director

Christine Malin

#### Production Coordinator

Joanne Patterson

#### Publishing Director/ Advertising

Wayne McCourt

#### Pharmaceutical Group Sales Director

Michael LoPresti

#### Advertising Sales Representative

Tina Panna

#### Advertising Sales Coordinator

Jill Campise

#### Classified/Recruitment Sales Manager

Kathy Huntley

#### Classified/Recruitment Sales Representative

Katie Ford

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

## CONTENTS

Continued from cover

**LETTERS TO THE EDITOR**

- Survival of *Acinetobacter* on Three Clinically Related Inanimate Surfaces**  
CAROL WEBSTER, PhD; KEVIN J. TOWNER, PhD; HILARY HUMPHREYS, MD 246
- 
- Creutzfeldt-Jakob Disease: Management of Accidental Contamination of Neurosurgical Instruments, Pathology Equipment, and Solutions**  
ELIZABETH ANN BRYCE, MD; KATERINA DOROVONI-ZIS, MD; DIANNE TRUDEAU; MARGARET SINCLAIR; FRED J. ROBERTS, MD 247
- 
- Disinfection of Hospital Laundry Using Ozone: Microbiological Evaluation**  
CLAUDIA CATELANI CARDOSO, DVM; JOÃO E. FIORINI, PhD; LUCIANO R. FERRIERA, PhD;  
JOSÉ W.B. GURJÃO, CHEMENG; LUIZ A. AMARAL, PhD 248
- 
- Impact of Nosocomial Infections on Outcome: Myths and Evidence (with reply)**  
ALEJANDRO E. MACÍAS, MD; JORDI RELLO, MD, PhD 248
- 
- Reasons That Healthcare Workers Decline Influenza Vaccination in a New Zealand Hospital Environment**  
CHRIS WALLS, MB, ChB, AFOM 249
- 
- Risk Factors for Nosocomial Infection in a High-Risk Nursery**  
RAHAMAN O. SUARA, MD; MICHAL YOUNG, MD; INEZ REEVES, MD 250
- 
- Once MRSA, Always MRSA? Setting up a Hospital Preadmission Questionnaire**  
JOHAN H.T. WAGENVOORT, MD, PhD; HUB M.J. TOENBREKER; THEO J. WERINK; HEIN H.G. BERENDSEN 251
- 
- BOOK REVIEWS**
- Hospital Infections, 4th ed (Bennett JV, Brachman PS)***  
KEITH F. WOELTJE, MD, PhD 285
- 
- Hospital Epidemiology and Infection Control, 2nd ed (Mayhall CG)***  
ROBERT H. LATHAM, MD 285
- 
- Antimicrobial Therapy and Vaccines (Yu VL, Merigan TC Jr, Barriere SL)***  
MICHAEL T. BRADY, MD 286
- 
- MEDICAL NEWS**  
GINA PUGLIESE, RN, MS; MARTIN S. FAVERO, PhD 287
- 
- SHEA NEWS**  
ANDREAS VOSS, MD, PhD 296

To view abstracts of these articles,  
visit us on the Internet at <http://www.slackinc.com/general/iche>

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

**PUBLISHER:** Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (856) 848-1000.

**SHEA:** 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 856-423-0087; fax, 856-423-3420; e-mail address, sheahq@talley.com.

**COPYRIGHT 2000** The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

**SUBSCRIPTIONS:** Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$110.00; Two years-\$148.00; Three years-\$181.00; Institutional: One year-\$133.00; Two years-\$183.00; Three years-\$233.00. Fellows: \$55.00 per year with proof of training status. Canada: \$20.00 additional each year plus 7% for Canadian Goods & Services tax; Overseas surface, \$150.00 each year; Overseas air mail, \$195.00. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.


**INSTRUCTIONS TO AUTHORS:** Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (<http://www.slackinc.com/general/iche/ichehome.htm>). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).

**REPRINTS:** All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (856) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

**CHANGE OF ADDRESS:** Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

**INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY** is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RNDex Top 100.

# All The Facts For Your Immunization Program



## Immunizing Healthcare Workers: A Practical Approach

Edited by Gregory A. Poland, MD; William Schaffner, MD; Gina Pugliese, RN, MS  
300 pp, Hard Cover, 2000, ISBN 1-55642-450-7, Order # 14507, \$109.00

**Immunizing Healthcare Workers: A Practical Approach** is the first complete resource for dealing with the immunization of healthcare workers. You can find all of the latest information on successfully and safely implementing or updating your immunization program in this landmark book.

Inside you will find that for each of the vaccine-preventable diseases among workers, there is a discussion of disease risks in the healthcare setting, vaccine recommendations, special administration strategies, safety issues, discussion of unresolved issues, and answers to commonly asked questions. There are also case studies of sample programs in specific settings.

This phenomenal book contains the latest recommendations from the US Public Health Service Advisory Committees, Healthcare Infection Control Practices Advisory Committee (HICPAC), and Advisory Committee on Immunization Practices (ACIP).

Read how the experts overcame obstacles setting up immunization programs in their health settings. With over 45 contributors to 32 chapters, **Immunizing Healthcare Workers: A Practical Approach** is an essential source for the information necessary to implement an effective immunization program.

Both textbooks are an official publication of  
**The Society of Healthcare Epidemiology (SHEA).**

### Some Case Study Topics:

- Immunizing Providers and Staff in Physicians' Offices
- Vaccination of Healthcare Workers in Long-Term Care Facilities for the Elderly
- Immunization of Affiliating Students and Contract Home Healthcare Workers
- Immunization Strategies for Home Healthcare Personnel
- Immunization of Workers with Altered Host Defenses
- Vaccinating Unimmunized and Partially Immunized Workers
- Assessing Immunity and Exposures: Using a Computerized Surveillance System
- Managing Information in an Immunization Program
- The Internet: A Quick Guide to Vaccine & Immunization Information

### ORDER FORM

Please send me \_\_\_\_\_ copies of **Immunizing Healthcare Workers: A Practical Approach** (Order # 14507) at **\$109.00** each.

Please send me \_\_\_\_\_ copies of **A Practical Handbook for Hospital Epidemiologists** (Order # 13020) at **\$65.00** each.

NJ residents add 6% sales tax \$ \_\_\_\_\_  
Handling \$ 4.50  
Total \$ \_\_\_\_\_

Name: \_\_\_\_\_




Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

E-mail: \_\_\_\_\_

Check enclosed (Payable to SLACK Incorporated)

Charge my:      

Account #: \_\_\_\_\_

<https://doi.org/10.1017/S0195941700054667> Published online by Cambridge University Press

Exp. date: \_\_\_\_\_ Signature \_\_\_\_\_

Prices are subject to change. Shipping charges may apply.

CODE: 1A448

### Also Available

**A Practical Handbook for Hospital Epidemiology**  
Edited by Loreen A. Herwaldt, MD and co-edited by Michael D. Decker, MD, MPH  
448 pp, Soft Cover, 1998, ISBN 1-55642-302-0,  
Order # 13020, \$65.00

**A Practical Handbook for Hospital Epidemiologists**  
most complete source for practical advice on hospital epidemiology. It is intended to be a pragmatic guide that will assist beginning and experienced practitioners in establishing and maintaining a successful hospital epidemiology program. This book will supplement the various scientific references available for this field and will help hospital epidemiologists improve their practices.

### Mail order form to:


SLACK Incorporated, Professional Book Division  
6900 Grove Road, Thorofare, NJ 08086-9447

Call: (800) 257-8290 or (856) 848-1000

Fax: (856) 853-5991

E-mail: [orders@slackinc.com](mailto:orders@slackinc.com)

World Wide Web Site: <http://www.slackinc.com>



## FEEL THE DIFFERENCE

When your career's at Tenet, you don't have co-workers. You have teammates. You have partners. You have friends. People who are there for you. To share your joy. And your sadness. You might call that a little thing. But to me, it made all the difference in the world.

A member of Tenet HealthSystem, Piedmont Healthcare System is a fully accredited, full-service healthcare facility located in Rock Hill, South Carolina, just 20 miles south of Charlotte, North Carolina. We're big enough to offer you plenty of opportunity, yet small enough to ensure you won't be just another name on an ID or another face in the crowd.

### Infection Control Coordinator

This position is responsible for coordinating infection control surveillance throughout the hospital. The qualified candidate should possess a South Carolina RN license, two years experience in a hospital nursing environment as well as infection control experience. Bachelor's degree in Nursing and certification in Infection Control are preferred.

Please mail or fax your resume to: **Piedmont Healthcare System, Human Resources Dept., 222 S. Herlong Avenue, Rock Hill, SC 29732. Phone (803) 329-6855. Fax (803) 329-6798. JOBLINE (803) 366-1400. EOE**

[www.teamtenet.com](http://www.teamtenet.com)



All the difference in the world.

A caring difference you can feel.

## Experience Outdoor Alaska in Minutes.


Located in Anchorage, Providence Alaska Medical Center offers you the unique opportunity to work just minutes from endless outdoor recreation and enjoy wildlife and adventures in everyday places. If you want to discover year-round adventures and great career potential, consider joining Providence Alaska.

### Program Coordinator, Epidemiology Services

Position supervises, coordinates and directs all epidemiological activities including infection control procedures and programs. Bachelors degree in Nursing or related health care field. Minimum of two years experience in Infection Control from a comparable facility. Knowledge of the principles of epidemiology is preferred.

Please send your resume to: **Providence Health System Alaska, Human Resources, PO Box 196990, 701 East Tudor, Suite 135, Anchorage, AK 99519; PHONE: (800) 478-9940; FAX: (907) 565 6499; Email: [bmcneil@provak.org](mailto:bmcneil@provak.org) EOE. Drug screening required**

For more information on Alaska, visit [www.state.ak.us](http://www.state.ak.us)



Providence Health System Alaska

[WWW.PROVIDENCE.ORG/ALASKA](http://WWW.PROVIDENCE.ORG/ALASKA)

# Mothers. Spouses. (maybe) Medical Matrix.

**What do they have in common? You place your trust in them.** When searching the Internet for credible medical information, you need a resource you can trust. *The Lancet* quotes that "Medical Matrix is the most comprehensive compendium of reliable medical information on the Internet."

## MEDICAL MATRIX<sup>LLC.</sup>

<http://www.medmatrix.org>

**The largest, peer-reviewed directory to the medical Internet.**

Free registration.